Clinical trials: Tumor Immunity, open to volunteers
Non Small Cell Lung Cancer, Healthy
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients.
- Trial name
- PROPHETIC (NCT05736029)
- Testing
- blood, stool and tissue samples collection
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- OncoHost Ltd.
Cervical Cancer Prevention
Study on the Safety, Humoral Immune Response, and Memory B Cell Response Characteristics of Sequential 9-Valent HPV Vaccination
This is a single-center, prospective, open-label, partially randomized, matched-controlled trial designed as a cohort study. The study plans to enroll 360 healthy female participants aged 18 to 45 years, divided into three…
- Trial name
- NCT07530679
- Testing
- 9-valent HPV vaccination at months 0 and 6, 9-valent HPV vaccination at months 0 , 1 and 6
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma
A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.
This study is being conducted to establish a novel tumor tissue- and blood-based biomarker test to assess early systemic and local response to immunomodulation by BCG immunotherapy in patients with high-risk non-muscle invasive…
- Conditions
- NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma, Bladder (Urothelial, Transitional Cell) Cancer, Urothelial Carcinoma Bladder
- Trial name
- BCG-TIME (NCT07064863)
- Testing
- Gemcitabine + BCG, BCG (TICE strain)
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Queen's University
Uveal Melanoma
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) alone or in combination with Ipilimumab and Nivolumab for patients with…
- Trial name
- NCT07364474
- Testing
- Melphalan through Percutaneous Hepatic Perfusion, Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Oncology
Potential of Moderate Whole Body Hyperthermia to Enhance Response
Using moderate whole-body hyperthermia (mWBH) in tumor patients to see the influence on circulating tumor cells, tumor response, quality of life, fatigue, psyche, immune response and tumor microenvironment
- Trial name
- POWER (NCT05821166)
- Testing
- moderate Whole Body Hyperthermia (mWBH)
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Charite University, Berlin, Germany
Gastric Cancer
InteGRAtive Analysis of TuMor, Microenvironment, ImmunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer
Multicentric, exploratory, non-pharmacologic, retrospective/prospective, translational study aiming to identify the molecular, cellular and psychological-sociological variables predictive of response to chemotherapy in gastric…
- Trial name
- GRAMMY (NCT04842916)
- Where
- 5 sites in France, Greece and 1 more
- Volunteers
- 250 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Solid Cancers
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy
This is a translational, open-label, multi-site, prospective cohort study aiming to identify and to monitor immunological biomarkers associated with therapeutic response to immune checkpoints blockade (ICB), in patients with…
- Trial name
- MINER (NCT03514368)
- Testing
- Patients treated with immune checkpoint blockade
- Where
- 3 sites in France
- Volunteers
- 770 people
- Sponsor
- Institut Claudius Regaud
Gastrointestinal Neoplasms
Interaction Between Host, Microenvironment and Immunity on Gastrointestinal Neoplasms
The primary objective: association study of characteristics of tumoral microenvironment and immunity of digestive cancers with patients' overall survival (OS).
- Trial name
- HoMING (NCT04363983)
- Testing
- Blood sampling, Liver biopsy, Stool collect
- Where
- France
- Volunteers
- 6,300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer - Female
Comparison Immune Response in Paravertebral and Erector Spinal Plane Block in Breast Cancer Patients
The goal of this clinical trial is to find the difference in immune response between two types of regional anesthesia in female patients suffering from breast cancer.
- Trial name
- IRPVBESP (NCT07648810)
- Testing
- Regional Anesthetic Injection, Blood draw for the laboratory assessment
- Volunteers
- 56 people
- Sponsor
- Clinical Hospital Center Rijeka
Cervical Dysplasia
The Mother-Daughter Project: Merck-4
This project serves to continue a community-based initiative, known as the Kenya Mother-Daughter Cervical Cancer Eradication Project, or the Mother-Daughter Project (MDP), in the Webuye region of Western Kenya.
- Trial name
- Merck-4 (NCT07240220)
- Testing
- Gardisil-9, High Risk HPV DNA Testing, Visual Inspection with acetic acid (VIA) and possible cervical biopsy
- Where
- Kenya
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Indiana University
Melanoma
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
To Determine the feasibility, compliance and adherence to PreFED intervention in resectable melanoma patients initiating neoadjuvant Ipi/Nivo.
- Trial name
- NCT06548789
- Testing
- Prebiotic Xnack Packouts
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
RSV Infection
RSV Vaccination in Immunocompromised Patients.
Respiratory syncytial Virus (RSV) causes respiratory infections worldwide and typically presents with a seasonal pattern peaking in autumn/winter in temperate climate zones.
- Trial name
- NCT06597916
- Testing
- Arexvy powder and suspension for injection
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Localized Cancer
Neo-adjuvant Immunotherapy Master Trial for Localized Cancers
Most cancer treatments are developed without knowing whether the drug's targets are actually present in a patient's tumor or whether the patient is likely to benefit from the treatment.
- Trial name
- NEOREM (NCT07262489)
- Testing
- Each therapeutic NEOREM sub-protocol will mention the description of intervention
- Where
- France
- Volunteers
- 200 people
- Sponsor
- UNICANCER
Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Observational, multicenter, one-arm, non-comparative study. Data will be recorded in a retrospectively manner. The study will be based on secondary data collected from patient clinical chart completed by the doctor during routine…
- Trial name
- SIENNA (NCT06634199)
- Testing
- Durvalumab
- Where
- 22 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Fundación GECP
Pancreatic Cancer
Predicting Pancreatic Fistula After Pancreatic Surgery Using Preoperative Immunity
The goal of this observational study is to develop and validate a preoperative immunological signature for predicting postoperative pancreatic fistula (POPF) in adult patients undergoing pancreatic surgery for pancreatic cancer.
- Trial name
- NCT07827911
- Testing
- blood sampling
- Where
- France
- Volunteers
- 310 people
- Sponsor
- Institut Paoli-Calmettes
Advanced Solid Tumor
Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
The main objective of this study is to test if adding the mistletoe extract Iscador® Qu to regular cancer treatment with immune checkpoint inhibitors affects: The immune system's ability to fight cancer Safety of the treatment…
- Trial name
- ISCA-CHECK (NCT06408688)
- Testing
- Immune checkpoint inhibitors plus Iscador® Qu., Immune Checkpoint Inhibitors
- Where
- 4 sites in Switzerland
- Volunteers
- 100 people
- Sponsor
- University Hospital, Basel, Switzerland
Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming
Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study
The goal of this clinical trial is to learn whether a high- and low-dose radiotherapy regimen followed by anti-angiogenic TKI and anti-PD-1 antibody therapy works to treat advanced metastatic colorectal cancer.
- Conditions
- Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response
- Trial name
- TRIUNITE-07 (NCT07467590)
- Testing
- High- and Low-Dose Radiotherapy, Anti-Angiogenic TKI and Anti-PD-1 Therapy
- Volunteers
- 33 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Head and Neck Squamous Cell Carcinoma
Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.
This is a single-center pharmacokinetic study evaluating the impact of residual pembrolizumab levels on the efficacy of salvage chemotherapy following immunotherapy in patients with non-small cell lung cancer (NSCLC) or recurrent…
- Trial name
- CPI (NCT07633613)
- Testing
- Blood sampling, Tumor biopsies for biobank establishment (optional)
- Volunteers
- 110 people
- Sponsor
- Centre Antoine Lacassagne
Tumor Immunity
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor
68Ga-DOTA-dPNE PET/CT imaging was performed on patients with malignant tumors to observe the binding of lesions with the tracer and evaluate the expression of CD73.
- Trial name
- NCT06844110
- Testing
- 68GA-DOTA-dPNE
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Glioblastoma
Impact of Fluorescence-Guided Resection and Chemoradiotherapy on the Systemic Immune Response in Glioblastoma: A Kinetic Analysis of Immune Biomarkers.
The immune system plays a critical role in cancer progression and antitumor responses. Glioblastoma is an aggressive and incurable brain tumor characterized by a highly immunosuppressive microenvironment.
- Trial name
- SHAM INDYGO/DO (NCT07568782)
- Testing
- Fluorescence-guided resection (FGR)
- Where
- France
- Volunteers
- 17 people
- Sponsor
- University Hospital, Lille